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Cisplatin is a major anticancer drug that kills cancer cells by damaging
their DNA. Cancer cells cope with the drug by removal of the
damages with nucleotide excision repair. We have developed
methods to measure cisplatin adduct formation and its repair at
single-nucleotide resolution. “Damage-seq” relies on the replica-
tion-blocking properties of the bulky base lesions to precisely
map their location. “XR-seq” independently maps the removal
of these damages by capturing and sequencing the excised oligomer
released during repair. The damage and repair maps we generated
reveal that damage distribution is essentially uniform and is dictated
mostly by the underlying sequence. In contrast, cisplatin repair is
heterogeneous in the genome and is affected by multiple factors
including transcription and chromatin states. Thus, the overall effect
of damages in the genome is primarily driven not by damage for-
mation but by the repair efficiency. The combination of the Damage-
seq and XR-seq methods has the potential for developing novel
cancer therapeutic strategies.
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Cisplatin [Cis-diamminedichloroplatinum(II)] is a major front-line drug in the treatment of lung, colorectal, ovarian, and
head-and-neck cancers (1) and has been used in the clinic since
1978. It kills cancer cells by damaging their DNA, mainly by forming
Pt-d(GpG) and, to a lesser extent, Pt-d(ApG), Pt-d(GpXpG)
intrastrand diadduct, and at lower frequency, Pt-G-G interstrand
cross-links (2–4). The cisplatin-induced damage is repaired by
nucleotide excision repair (5–8). In excision repair, the damage in
DNA is excised from the genome as a single-stranded oligomer of
∼30 nt. The single-stranded gap in the genome is filled in by DNA
polymerases and ligated, resulting in error-free repair. Although
cisplatin is effective in the treatment of the indicated types of
cancers, in some of the cases, drug resistance is observed. The
cause of the resistance is multifactorial, and DNA repair is con-
sidered to be one of the contributing factors, although the degree
to which DNA repair contributes to resistance is still unclear.
Here, we describe the development of methods to measure cis-
platin adduct formation and repair at single-nucleotide resolution.
Using these methods, named “Damage-seq” and “eXcision Repair-
seq” (XR-seq), we have generated single-nucleotide resolution
maps for both the damage induced by cisplatin and its removal by
nucleotide excision repair (9, 10). Our method should be appli-
cable for studying drug resistance and for optimization of cancer
chemotherapy regimens.
Results
In this work, we present the cisplatin damage and repair maps for
the entire genome of the human lymphocyte cell line GM12878.
This cell line was chosen because it has been extensively charac-
terized by the ENCODE project (11). Similar experiments with
oxaliplatin, a third generation derivative of cisplatin, yielded
similar results and are presented in SI Appendix, SI Materials and
Methods. All experiments were performed with two biological
replicates.
Cisplatin DNA Damage Map. We developed the method of Dam-
age-seq based on the fact that bulky DNA adducts block high-
fidelity DNA polymerases (2, 12). Here, we have applied
Damage-seq to construct a human genome DNA damage map
for cisplatin-induced damage. In Damage-seq (Fig. 1A and SI
Appendix, Fig. S1), cells were treated with cisplatin and the
genomic DNA was isolated and fragmented by sonication. Then
the fragment ends were repaired, followed by ligation of the
first adapter. Next, the DNA was denatured and immunopre-
cipitated with anti-Pt antibodies to isolate the ssDNA frag-
ments containing the Pt adduct. Then, a biotinylated primer
was annealed to the adapter and extended by NEBNext Q5
DNA polymerase. The extended primers were purified by
streptavidin-coated beads. The second adapter was then ligated,
followed by PCR with index primers. To check the quality of the
libraries, 1% of the ligation products were amplified by two sets of
primers corresponding to the first or second adapters and ana-
lyzed on agarose gels (Fig. 1B and SI Appendix, Fig. S2A). The
first primer set supports amplification of only unblocked extension
products from the undamaged strand, whereas the second set
of primers amplifies all products from both damaged and un-
damaged strands. If the majority products came from the dam-
aged strands, PCR products by the second primer set would be
shorter and at a much higher level than those by the first primer
set, which can only generate products from undamaged strands
(Fig. 1B, compare lanes 2 and 4, and SI Appendix, Fig. S2A). In
contrast, if most of the PCR products came from undamaged
strands, the second set of primers would generate slightly longer
PCR products (Fig. 1B, compare lanes 1 and 3). After sequencing,
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reads from undamaged DNA, which began with the 5′ sequence of
the first adapter, were discarded before alignment and data
analysis.
Cisplatin DNA eXcision Repair (XR-seq) Map. An XR-seq library for
cisplatin damage was prepared by adapting the XR-seq method we
previously developed for UV damage to cisplatin damage repair
(13–15), with modifications in the steps of damage-specific im-
munoprecipitation and in vitro damage reversal (Fig. 1A, Right):
After cisplatin treatment, primary excision products were pulled
down by transcription factor IIH (TFIIH) coimmunoprecipitation
and ligated to adapters on both ends. This step was followed by
immunoprecipitation with cisplatin-specific antibodies (16). The
Pt-DNA adducts in the immunoprecipitated oligomers were re-
versed by incubating in NaCN (5–8). Then, the oligomers were
amplified by PCR to obtain the XR-seq high-throughput sequencing
library (Fig. 1C and SI Appendix, Fig. S2B). The reads were then
aligned to the human genome to generate the XR-seq map for
cisplatin-induced repair of the human genome.
Cisplatin Damage-seq and XR-seq Products. Cisplatin mainly forms
Pt-d(GpG) and, to a lesser extent, Pt-d(ApG), Pt-d(GpXpG) intra-
strand diadduct, and at a lower frequency, Pt-G-G interstrand cross-
links (2–4). According to the Damage-seq procedure (Fig. 1A), the
cisplatin lesion should be at the nucleotides immediately 5′ (up-
stream) of our reads. Thus, when we aligned the filtered reads to the
human genome, it was expected that the dinucleotides 5′ upstream
will be diguanines (G-G and, to a lesser extent, A-G). In agreement
with the prediction, G-G was highly enriched 5′ to the read start with
cisplatin damaged DNA but not with undamaged DNA (Fig. 2 A vs.
C, and SI Appendix, Fig. S3 and Table S1). Moreover, we uncovered
a preference for A 5′ to the G-G dinucleotides of our Damage-seq
reads (Fig. 2 B vs. D and SI Appendix, Fig. S4).
XR-seq for cisplatin-damaged cells revealed oligonucleotide-
length distribution essentially identical to that observed with UV
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Fig. 1. Damage-seq and XR-seq methods. (A) Schematic representation of the methods. Red stars indicate the Pt-DNA adducts. In Damage-seq (Left), after
damage induction, genomic DNA was sonicated and subjected to end repair. Then these end-repaired fragments (black) were ligated to the first adapters
(green). This step was followed by denaturation and IP with an antibody against cisplatin adducts. Next, a biotinylated primer (purple) was annealed and
extended by a DNA polymerase, which was blocked by DNA damage. The extension products (red) were purified and ligated to the second adapter (blue).
Finally, the ligation products were amplified with index primers and sequenced. In XR-seq (Right), the 22- to 30-nt-long oligomers generated by nucleotide
excision repair (black) were captured by IP with TFIIH antibodies and followed by ligation with adapters on both ends (blue and red). Then, the ligation
products were purified by IP with the anti-cisplatin antibody, and the Pt adducts were reversed by incubation with NaCN. Finally, the oligomers were am-
plified and sequenced. For clarity, in both Damage-seq and XR-seq, the lengths of the DNA fragments and adapters are not drawn to scale. (B) Representative
agarose gel analysis of Damage-seq libraries. DNA fragments from control and cisplatin-treated cells were amplified with sets of primers complementary to
the first and second adapters. (C) Representative native polyacrylamide gel electrophoresis of XR-seq libraries (1% of material) showing cisplatin adduct
reversal by NaCN is necessary for PCR amplification of sequencing libraries.
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photoproducts with 26- to 27-nt-long excision products pre-
dominating (SI Appendix, Fig. S7) (5–8, 17). In contrast to the
excision products of UV damage, the cisplatin XR-seq products
contained G-G at ∼20 nt from the 5′ and 5–6 nt from the 3′ end
of the 26-nt-long excised oligomer (Fig. 2E and SI Appendix, Fig.
S6A and Table S2), consistent with the fact that Pt-d(GpG) is the
predominant DNA adduct of cisplatin. This location of the
adduct indicates that regardless the type of damage (UV or
cisplatin-induced lesions), the dual incision sites characteristic
of nucleotide excision repair (17) are virtually the same. In
C D
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Fig. 2. Single-nucleotide resolution of cisplatin damage and repair. (A) Nucleotide frequencies are plotted for positions 3 nt upstream of the read start and
10 nt into the read for cisplatin Damage-seq. (B) Sequence context for the 5 nt flanking the most common dinucleotide associated with Pt damage. (C and D)
Same as A and B except plotted are results for sequenced undamaged control DNA. (E) Frequency of the G-G dinucleotide at each position of 26-nt-long
XR-seq excision fragments. (F) Nucleotide frequencies at the 5-nt flanking G-Gs at positions 19–20. Figures depict data from a representative experiment.
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Fig. 3. Genome-wide patterns of damage and repair of cisplatin damage. (A) Representative screen shot of damage and repair signals, separated by strand, for
the entire chromosome 17. (B) Zoom-in on A ∼80-kbp segment of chromosome 17, which includes TP53. (C) Representative XR-seq and Damage-seq reads that
capture a specific Pt-d(GpG) damage. (D) Damage and repair profiles of the transcribed and nontranscribed strands surrounding TSS of highly expressed genes.
(E) Zoomed-in scale for the damage levels. (F) Same as E except plotted are GG frequencies on each strand. Data normalized per million mapped reads or million
counted GGs. Figures represent data from merged replicates.
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contrast to Damage-seq, there was a preference for T 5′ and G 3′
of the G-G dinucleotides in XR-seq reads (Fig. 2F and SI Ap-
pendix, Fig. S6B), indicating a possible sequence context pref-
erence for excision. We cannot discriminate whether these
G-G-G sequences are a sequence context preference for
Pt-d(GpG) excision or excision of Pt-d(GpXpG).
Genome-Wide Maps of Cisplatin Damage and Repair. Our ability to
map damage and repair genome-wide provided the data necessary
to examine the determinants of damage sensitivity throughout the
genome (Fig. 3 A–C and SI Appendix, Fig. S7–S9). As an example,
we focused on chromosome 17, which carries the TP53 gene that is
mutated in approximately 50% of human cancers. We followed
repair from a chromosome-wide scale (Fig. 3A) to a more focused
gene-centric analysis (Fig. 3B) and, finally, to single nucleotides at
a specific cisplatin-d(GpG) damage site in TP53 that was captured
by representative Damage-seq and XR-seq reads (Fig. 3C).
As apparent from the high-resolution data, whereas cisplatin
damage distribution was essentially uniform the repair efficiency
was rather heterogeneous. This difference was particular striking
when damage and repair of Pt adducts in the transcribed strand
of TP53 were compared.
To analyze the effect of transcription on damage and repair
genome-wide, we plotted damage and repair levels surrounding
the transcription start sites (TSS; Fig. 3 D and E) and tran-
scription end sites (TES; SI Appendix, Fig. S10) of highly
expressed genes in GM12878 cells (11). Similar to CPD repair
(18, 19), cisplatin repair was transcription coupled, with higher
repair of the transcribed strand, starting from TSS and con-
tinuing up to the TES. In comparison with the repair levels,
damage levels appeared virtually uniform. However, upon close
inspection at high resolution we did observe subtle differences in
damage levels at the starts and ends of genes (Fig. 3E and SI
Appendix, Fig. S10): Pt damage was slightly enriched over the
TSS and slightly depleted over the TES. To determine whether
this enrichment was due to the unique features of TSS or a
simple reflection of the cisplatin target dinucleotide sequence
frequencies, we analyzed G-G frequency in the TSSs of the same
group of genes: The G-G frequency at TSS and TES mirrored
the Pt-d(GpG) damage (Fig. 3F and SI Appendix, Fig. S10).
Effect of Nucleosome and Chromatin States on Damage Formation and
Repair. To detect possible effects of nucleosome occupancy on
damage formation and repair, we used existing nucleosome
mapping data from GM12878 (11) and plotted damage levels
surrounding the center of nucleosome positions. We observed a
distinct periodicity of damage formation surrounding the center
position of nucleosomes (“in vivo”, Fig. 4A). However, a similar
periodicity was observed when we plotted damage formation in
cisplatin-treated naked DNA (“in vitro”) or the frequency of the
CA
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Fig. 4. Effect of nucleosomal location and chromatin states on cisplatin damage formation and repair. (A) Average in vivo Damage-seq (red), in vitro
Damage-seq (pink), and the relevant dinucleotide frequency (gray) at 1 Kbp flanking the center of nucleosomes in GM12878 cells. (B) Similar to A, except
plotted is ratio of in vivo to in vitro cisplatin damage. Mnase-seq nucleosomal signal is plotted for comparison. (C) Similar to B, except plotted is the ratio of
repair to damage. (D) Analysis of repair (Upper) and damage (Lower) levels across the 15 annotated chromatin states of GM12878 for cisplatin damage reveals
uniform distribution of damage but higher repair levels in open regions in the genome. Figures represent data from merged replicates.
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G-G dinucleotide, indicating that the damage periodicity simply
reflects the periodicity of the target dinucleotide. In Fig. 4B, we
plot the ratio of cisplatin damage in vivo to in vitro at the same
positions. We see a slight dip in the ratio at the nucleosome cen-
ters, indicating that adduct formation near the nucleosome center
was inhibited, albeit at a level of ∼5% relative to other positions.
In contrast to damage formation, Fig. 4C shows that repair
efficiency exhibited periodicity that was antiphase with the nu-
cleosome center, which is consistent with nucleosomes making
cisplatin DNA adducts refractory to repair (8). These results
agree with the observation that repair is strongly associated with
DNase-HS sites (SI Appendix, Fig. S11 and refs. 13 and 14),
whereas damage levels are relatively uniform.
Finally, we analyzed the association of 15 chromatin states
with DNA repair. The chromatin states are derived from histone
posttranslational modifications and genomic sequence elements,
with functional roles inferred for each state (20). We found that
similar to the repair of UV damage [CPD and (6, 4)photo-
products] (13, 14), Pt-damage repair was higher in active chro-
matin states such as active promoters and strong enhancers (Fig.
4D and SI Appendix, Fig. S12A, Top). In stark contrast, the dis-
tribution of the damages, with some minor differences, was
rather uniform (Fig. 4D and SI Appendix, Fig. S12A, Bottom).
The subtle differences in damage frequency that were observed
as a function of genomic position followed differences in the
underlying frequencies of the relevant dinucleotide, d(GpG) (SI
Appendix, Fig. S12B).
Discussion
Although cisplatin and its second- and third-generation deriva-
tives have been used for decades with considerable success in
cancer management (1–4), some cancers exhibit primary or ac-
quired resistance limiting its general usefulness. Because cis-
platin-induced DNA damage is repaired by nucleotide excision
repair, the role of this repair mechanism in cisplatin efficacy or
resistance needs to be delineated. Previous studies have used
global genome repair assays to address this issue but the results
have been inconclusive (1–8). High resolution maps of DNA
damage formation and repair would aid in understanding the
genomic variables that affect sensitivity to genotoxic agents.
Methods for mapping cisplatin (21) and UV (21–26) damage in
yeast and human cells have been described. However, whereas
CPDs can be mapped at high resolution (22, 25), the utility of
mapping of cisplatin has been limited because of the low reso-
lution and the lack of strandedness. Moreover, these maps were
not accompanied with the corresponding repair maps, which are
necessary for making extrapolations vis a vis damage location-
repair-biological end points.
Here, we present methods for single-nucleotide resolution
mapping of cisplatin damage and repair. We show that cisplatin-
induced DNA damage is essentially uniformly distributed in the
human genome, and damage incidence is dictated primarily by
the underlying G-G frequency. This finding is in agreement with
a previous low-resolution study that mapped cisplatin and oxali-
platin damage (21). Comparing in vivo and in vitro damage for-
mation at nucleosomes indicates nucleosome binding affords a
small degree of protection from cisplatin damage formation. We
do not observe the strong effect of nucleosome rotational setting
on damage formation as was reported for CPDs in a recent high-
resolution study in yeast (25). This observation may be due to an
inherent difference between cisplatin and UV damage formation,
or between yeast and human nucleosome organization. We cannot
rule out, however, that compared with the yeast study, which used
high-resolution nucleosome positions, the nucleosome mapping
available for GM12878 is less accurate. Less accurate positions
would compromise our ability to precisely measure damage for-
mation relative to the nucleosome centers, and the protection may
be higher than we report.
In stark contrast to damage formation, the efficiency of repair is
highly heterogeneous and significantly correlated to transcription
and chromatin states. Thus, the overall effect of damages in the
human genome is primarily driven by the repair efficiency and not
by damage formation. Cisplatin resistance, primary or acquired, is
multifactorial likely encompassing uptake, efflux, drug inactivation
by sulfhydryl groups, and finally repair. We believe that the single-
nucleotide resolution methods for cisplatin damage and repair we
have described in this paper should aid in determining the con-
tribution of repair to cisplatin efficacy or resistance as our previous
XR-seq data has for UV mutagenesis (14, 27, 28). This goal will
require the generation of damage and repair maps in cancers from
different tissues. Then, it would be possible to develop rational
approaches to overcome cisplatin resistance and improve the ef-
ficacy of cisplatin treatment. We note that the Pt-based drugs form
interstrand cross-links at low frequency (1–4). Our method, in its
present form, does not detect the formation and repair of these
damages. However, it is generally accepted that these rare inter-
strand cross-links do not substantially contribute to Pt drug effi-
ciency and toxicity. Finally, we note that Damage-seq should be
applicable to the study of damage and repair of other carcinogens
and chemotherapeutic drugs.
Materials and Methods
Human lymphocyte cell line GM12878 was grown to ∼8 × 105 cells per mL
before treatment. For Damage-seq and XR-seq, cells were incubated in
media containing 200 μM cisplatin or oxaliplatin for 1.5 and 3 h, respectively.
Damage-seq detected Pt-adducts based on the blockage of DNA polymerase
in vitro by damage. Pt-XR-seq was modified from UV-XR-seq. (13). Detailed
description of the methods and data analysis is found in SI Appendix, SI
Materials and Methods.
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